)
Dr Reddy's Laboratories today said it has entered into strategic collaboration with US-based multinational biotechnology company Amgen to market and distribute three of its medicines in India in the areas of oncology and cardiology.
Under the terms of the deal, Dr Reddy's shall seek approval and launch Kyprolis(carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in the country.
"Dr Reddy's has significant experience serving oncology and cardiovascular patients in India and shares Amgen's interest in delivering new treatment options to seriously ill patients," said Penny Wan, Amgen vice president and general manager, Japan Asia Pacific Region.
Kyprolis was approved by the US Food and Drug Administration in July 2015, in combination with lenalidomide and dexamethasone, for the treatment of patients with relapsed multiple myeloma, who have received one to three prior lines of therapy.
BLINCYTO is an example of immunotherapy while Repatha, which was granted marketing authorisation by the European Commission (EC) in July this year, is used to control cholesterol.
